Cure8 research brief
This preclinical mouse study identifies nitidine chloride as a plant-derived compound that reduced inflammation, improved gut barrier markers, and reshaped the gut microbiota and metabolome in a model of ulcerative colitis — suggesting a potential lead for future anti‑UC research.
These mechanistic findings could inform future translational studies focused on microbiome and barrier-targeted therapies.
Researchers (microbiome, drug discovery, intestinal barrier), clinicians following translational IBD research, and drug-development teams interested in natural-product leads.
This study used a DSS-induced ulcerative colitis mouse model to compare two plant-derived alkaloids (nitidine chloride and chelerythrine chloride).
Nitidine chloride (NC) reduced weight loss and improved organ indices and markers of colonic inflammation and barrier integrity in mice, and altered the gut microbiota and serum metabolites toward patterns the authors describe as beneficial.
The authors report NC decreased pro-inflammatory signals (including COX-2) and intestinal permeability markers (DAO, D‑lactate), increased tight-junction proteins (Claudin-1, ZO‑1) and MUC2, and enriched taxa such as Akkermansia and Limosilactobacillus.
They also performed 16S rRNA sequencing, metabolomics, correlation analyses, and in silico network pharmacology/molecular docking to explore potential targets.
These experiments were done in mice and include multi-omics and computational analyses; they serve as preclinical mechanistic data supporting NC as a candidate natural compound for further anti‑UC research. This is not clinical evidence and does not establish safety or efficacy in people.
Results come from a DSS-induced ulcerative colitis mouse model and multi-omics plus in silico analyses described in the article abstract. This is preclinical/basic-science evidence; it does not demonstrate safety or efficacy in humans.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study identifies a compound that improved inflammation, barrier integrity, and microbiome/metabolite signatures in a mouse model of ulcerative colitis—areas that matter for symptom control and disease biology in...
This preclinical study connects an herbal medicine to changes in gut microbiota, inflammation, and intestinal barrier function in a mouse model of ulcerative colitis — findings that could inform future research on new...
This study identifies a plant-derived compound (poricoic acid A) that reduced inflammation, cellular senescence, and colon injury in cell and mouse models of ulcerative colitis and links those effects to AMPK/PPARγ...
